A 6-month clinical study with active therapeutic intervention was carried out to evaluate the efficacy of moxonidine for the correction of arterial hypertension in 30 patients with metabolic syndrome. Along with the metabolic neutrality for the lipid and purine metabolism, the drug demonstrated a distinct antihypertensive effect, which against the background of pronounced sympatholytic action after 3 months of therapy tends to disappear, which can be prevented by dosage correction. It was shown that the efficacy of moxonidine in reducing insulin resistance in patients with metabolic syndrome directly depends on the severity of hypersympathicotonia manifesting in heart rate over 80 bpm at rest.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
A. N. Brittov, Trudny Patsient, No. 8, 65–70 (2006).
Y. A. Vasyuk, I. A. Sadulayeva, E. N. Yushchuk, et al., Arterial. Giperten., 13, No. 2, 13–19 (2007).
T. Ju. Demidova, A. S. Ametov, and L. V. Smagina, Obzory Klin. Kardiol., 4, 21–30 (2006).
A. O. Konrady, Arterial. Giperten., 12, No., 2–9 (2006).
V. O. Konstantinov and Ya. R. Sayfulina, Ibid., 13, No. 3, 195–196 (2007).
V. I. Makolkin, Rus. Med. Zh., No. 16, 1238–1241 (2007).
S. V. Moiseev, Klin. Farmakol. Ter., No.4, 70–74 (2004).
R. G. Oganov, M. N. Mamedov, and I. E. Koltunov, Vrach, 3, 3–7 (2007).
G. E. Roitberg, Metabolic Syndrome [in Russian], Moscow (2007).
R. H. Eckel, S. M. Grundy, and P. Z. Zimmet, Lancet, 365, 1415–1428 (2005).
C. Fenton, G. M. Keating, and K. A. Lyseng-Williamson, Drugs, 66, No. 4, 477–496 (2006).
S. M. Grundy, Nat. Rev. Drug Discov., 5, No. 4, 295–309 (2006).
A. F. Sanjuliani, V. Genelhu de Abreu, J. Ueleres Braga, et al., J. Clin. Basic. Cardiol., 7, 19–25 (2004).
A. M. Sharma, T. Wagner, and P. Marsalek, J. Hum. Hypertens., 18, No. 9, 669–675 (2004).
P. Zimmet, K.G. Alberti, and M. Serrano Rios, Rev. Esp. Cardiol., 58, No. 12, 1371–1376 (2005).
Author information
Authors and Affiliations
Corresponding author
Additional information
Translated from Byulleten’ Eksperimental’noi Biologii i Meditsiny, Vol. 151, No. 4, pp. 380–384, April, 2011
Rights and permissions
About this article
Cite this article
Kseneva, S.I., Borodulina, E.V., Semiglazova, T.A. et al. Pecularities of Prolonged Use of Moxonidine in Patients with Hypertension Associated with Metabolic Syndrome. Bull Exp Biol Med 151, 400 (2011). https://doi.org/10.1007/s10517-011-1341-9
Received:
Published:
DOI: https://doi.org/10.1007/s10517-011-1341-9